Navigation Links
Sorrento Therapeutics to Present at Two Healthcare Conferences
Date:9/6/2013

s also developing therapeutics products for other indications, including inflammation, metabolic, and infectious diseases. Sorrento Therapeutics' proprietary G-MAB® fully-human antibody library platform was designed to facilitate the rapid identification and isolation of highly specific antibody therapeutic product candidates that bind to disease targets appropriate for antibody therapy. Sorrento Therapeutics is also developing proprietary antibody drug conjugates (ADCs) as well as antibody formulated drug conjugates (AfDC) combining its G-MAB® antibodies and anti-tumor agents. On March 7, 2013, we entered into an exclusive option agreement with IgDraSol, Inc., a private company focused on developing oncologic agents for the treatment of metastatic breast cancer, or MBC, non-small cell lung cancer, or NSCLC, and other cancers.

More information is available at www.sorrentotherapeutics.com

Forward-Looking Statements

This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. Words such as "assumes," "plans," "believes," "expects," "anticipates," and "will," and similar expressions, are intended to identify forward-looking statements. Forward-looking statements include statements about the preclinical and clinical development of Sorrento's human antibody therapeutics. All such forward-looking statements are based on Sorrento's current beliefs and expectations, and should not be regarded as a representation by Sorrento that any of its plans will be achieved. Actual results may differ materially from those set forth in this press release due to the risks and uncertainties inherent in Sorrento's businesses; the scope and validity of patent protection for Sorrento's platform technologies, and the risk that the development or commercialization of product candidates may infringe the in
'/>"/>

SOURCE Sorrento Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Sorrento Therapeutics and Ben-Gurion University Sign an Agreement for the Development of Anti-Hepatitis C Virus Antibodies
2. Sorrento Therapeutics and IGDRASOL to Present Late Stage Clinical Data Updates on their Oncology Nanomedicine Platform at the Joint Meeting of the European Foundation for Clinical Nanomedicine and European Technology Platform on Nanomedicine in Base
3. Sorrento Therapeutics Receives Frost & Sullivans Prestigious 2013 Global Investment Opportunity Award in the Oncology Market
4. Sorrento Therapeutics Receives Frost & Sullivans 2013 Global Investment Opportunity Award in Oncology
5. Sorrento Therapeutics to Present at the Jefferies 2013 Global Healthcare Conference in New York City
6. Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases
7. Sorrento Therapeutics, Inc. and IGDRASOL Announce Presentation on Non-Biologic Nanoparticle paclitaxel (NBN-Pac) Formulations for the Treatment of Solid Tumors at the Nanomedicine 2013 Meeting in Barcelona, Spain
8. Sorrento Therapeutics Signs Exclusive Option to Acquire IGDRASOL
9. Sorrento Therapeutics Awarded Third Phase I STTR Grant
10. Mast Therapeutics Hosting 2nd Annual Sickle Cell Disease Therapeutics Conference On September 19, 2013
11. Signature Therapeutics, Inc., Presents Four Scientific Posters Today at PAINWeek 2013 Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... SOUTH SAN FRANCISCO, Calif. , March 2, ... therapeutics for the treatment of cancer, today announced ... comprised of leading researchers and clinicians in the ... The new advisory boards will ... its wholly owned pipeline of precision immunotherapies and ...
(Date:3/2/2015)... , March 2, 2015   Mast ... biopharmaceutical company, today announced preliminary findings from a ... a model of chronic, stable heart failure produced ... study was to examine the effects of repeat ... systolic and diastolic function. Consistent ...
(Date:3/2/2015)... 2015  Delcath Systems, Inc. (NASDAQ: DCTH ... on oncology with an emphasis on the treatment of ... will participate in the upcoming 27 th Annual ... the Ritz Carlton Laguna Niguel in Dana ... MSN, CRNP, Delcath,s interim President and Chief Executive Officer, ...
Breaking Medicine Technology:CytomX Expands Scientific and Clinical Advisory Boards with Leading Experts in Cancer Immunotherapy and Antibody Drug Conjugates 2CytomX Expands Scientific and Clinical Advisory Boards with Leading Experts in Cancer Immunotherapy and Antibody Drug Conjugates 3Mast Announces Results From Nonclinical Study Investigating Repeat Treatment With Vepoloxamer In Advanced Heart Failure 2Mast Announces Results From Nonclinical Study Investigating Repeat Treatment With Vepoloxamer In Advanced Heart Failure 3Mast Announces Results From Nonclinical Study Investigating Repeat Treatment With Vepoloxamer In Advanced Heart Failure 4Mast Announces Results From Nonclinical Study Investigating Repeat Treatment With Vepoloxamer In Advanced Heart Failure 5Mast Announces Results From Nonclinical Study Investigating Repeat Treatment With Vepoloxamer In Advanced Heart Failure 6Delcath To Present At The 27th Annual Roth Conference 2Delcath To Present At The 27th Annual Roth Conference 3
... The Epilepsy Foundation recently announced findings that show ... a consistent drug therapy, have a greater chance of ... their medications are switched from one version of an ... brand-to-generic, generic-to-brand or generic-to-generic. See video from the Epilepsy ...
... Findings Reinforce March of Dimes Message: Start Taking a ... 11 Women who take folic acid supplements for ... cut their risk of having a premature baby by ... online journal, PLOS Medicine.The study links pre-conceptional folate supplementation ...
Cached Medicine Technology:VIDEO from Medialink and the Epilepsy Foundation: New Study Suggests Different Versions of the Same Epilepsy Medication Can Be Harmful 2Taking Folic Acid for a Year Before Pregnancy May Reduce Risk of Preterm Birth 2
(Date:3/2/2015)... 02, 2015 LegitScript, LLC, ... certification programs, including those for Internet pharmacy ... safety and classification, has launched a certification ... The new program, called iCareRx , ... regarding the identity of the owner/operator of ...
(Date:3/2/2015)... 02, 2015 Regulatory Compliance Associates® ... quality, regulatory and technical consulting, announces Mr. Seyed ... Officer. , Before joining RCA, Mr. Khorashahi ... teams in all aspects of developing safety-critical medical ... Covidien (Medtronic), Regulatory Compliance Associates Inc., Baxter Healthcare, ...
(Date:3/2/2015)... 02, 2015 The Alliance for Bangladesh ... expert Mark Chubb to serve as chief safety officer. ... and training in Bangladesh and guide remediation efforts in ... “Mark will ensure that the Alliance continues to bring ... for Bangladesh garment workers,” said Alliance Independent Chair Ellen ...
(Date:3/2/2015)... 2015 Final Cut Pro X ... 2 from Pixel Film Studios. , “The TranStatic Volume 2 ... said Christina Austin, CEO of Pixel Film Studios. “TranStatic Volume ... Cut Pro X editors toolbox.” , With TranStatic Volume 2 ... media altering static scrambling effects from Pixel Film Studios. Users ...
(Date:3/1/2015)... As residents and business owners in ... and Carita Weaver, believe in supporting local organizations ... Southlake Chamber of Commerce, Carroll Independent School District ... a website for Southlake mayoral candidate Laura Hill: ... for Hill’s campaign, the website combines images, videos ...
Breaking Medicine News(10 mins):Health News:LegitScript Launches Certification Program for Internet Eyeglass Sellers 2Health News:Regulatory Compliance Associates® Inc. Welcomes Seyed Khorashahi as Chief Operating Officer 2Health News:Alliance for Bangladesh Worker Safety Names New Chief Safety Officer 2Health News:Pixel Film Studios released the TranStatic Volume 2 plugin for Final Cut Pro X today 2Health News:Website Launched for Southlake, Texas Mayoral Candidate Laura Hill 2
... older women with breast cancer lag behind younger women diagnosed ... missing out on improvements in treatment and detection, according to ... Center. The study, published in the Journal of ... whether the improvements made in breast cancer outcomes over the ...
... 2011) AMRI (NASDAQ: AMRI) announced today that, as ... and Company, it anticipates hiring more than 40 synthetic ... Lilly,s drug discovery programs. The chemists will work onsite ... support the medicinal chemistry department. This collaboration will ...
... Jenifer Goodwin HealthDay Reporter , MONDAY, Nov. ... child with autism or with a milder form of ... only by the child,s symptoms, but by where the ... found wide variability at autism centers across the nation ...
... CA The University of California, Santa Barbara ... Grand Challenges Explorations, an initiative created by the ... worldwide to test unorthodox ideas that address persistent ... Amr El Abbadi in the Computer Science Department ...
... The Lymphoma Division of the John Theurer Cancer Center at ... groups "Hope for Lymphoma" and "Our MCL Family," will host ... from 8:30am 3:45pm. The event is open to ... patients and their caregivers coping with this challenging diagnosis. ...
... HealthDay Reporter , SUNDAY, Nov. 6 (HealthDay News) -- ... the holiday season for some. For others, those airborne ... and sneezing to asthma attacks. Allergists say as ... complaints from their patients about reactions to them. ...
Cached Medicine News:Health News:UT MD Anderson study finds advances in breast cancer don't extend to older women 2Health News:UT MD Anderson study finds advances in breast cancer don't extend to older women 3Health News:Where a Child Is Tested May Affect Autism Diagnosis 2Health News:Where a Child Is Tested May Affect Autism Diagnosis 3Health News:UC Santa Barbara receives Grand Challenges Explorations funding 2Health News:UC Santa Barbara receives Grand Challenges Explorations funding 3Health News:John Theurer Cancer Center to host inaugural Mantle Cell Lymphoma Symposium 2Health News:John Theurer Cancer Center to host inaugural Mantle Cell Lymphoma Symposium 3Health News:Air Fresheners, Scented Candles May Spur Allergic Reactions 2Health News:Air Fresheners, Scented Candles May Spur Allergic Reactions 3
Portex® Blue Line® cuffed endotracheal tubes come in a wide selection of sizes, each with a standard 15 mm ISO connector., ,Portex® Blue Line® endotracheal tubes are recognized world...
Ruschelit® PVC. Murphy eye-nasoral. X-ray opaque line. Graduated. Single use. Sterile...
Ruschelit® PVC. Magill tip - nasoral. X-ray opaque line. Graduated. Single use. Sterile...
... Tube with stylet inside. Sterile, Latex ... Rusch endotracheal tube with a preloaded ... saving you time and storage space. ... easy identification and has a stopper ...
Medicine Products: